# US 6,294,582 B1 · Methods for treatment of asthma using S-oxybutynin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,294,582 B1
- Document ID: US6294582B1
- Status: Granted
- Kind: B1
- Application number: 09/574,106
- Filed: 2000-05-17
- Granted: 2001-09-25
- Earliest claimed: 1999-05-20
- Assignees: Sepracor Inc.
- Inventors: Thomas P. Jerussi
- Web page: https://patentgrep.com/patent/US6294582B1

## CPC

- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61P 11/06: Antiasthmatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Substantially optically pure S-oxybutynin, or a pharmaceutically acceptable salt thereof, is administered as a treatment for asthma. Such treatment is provided while reducing the adverse effects associated with the administration of racemic oxybutynin.

## Claims

### Claim 1

A method of treating reversible obstructive pulmonary disease comprising administering to an individual in need of such therapy a therapeutically effective quantity of substantially optically pure S-oxybutynin, or a pharmaceutically acceptable salt thereof.

### Claim 2

A method of treating reversible obstructive pulmonary disease while reducing the adverse effects associated with the administration of racemic oxybutynin comprising administering a therapeutically effective quantity of substantially optically pure S-oxybutynin, or a pharmaceutically acceptable salt thereof, to an individual in need of such therapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein treating reversible obstructive pulmonary disease comprises inducing bronchodilation.

### Claim 4 (depends on 1)

The method of claim 1, wherein treating reversible obstructive pulmonary disease comprises relieving or preventing bronchoconstriction.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutically effective quantity is a quantity sufficient to reverse or prevent bronchospasms.

### Claim 6 (depends on 1)

The method of claim 1, wherein the substantially optically pure S-oxybutynin comprises at least 98% by weight of the S-isomer and 2% or less by weight of the R-isomer.

### Claim 7 (depends on 1)

The method of claim 1, wherein S-oxybutynin is administered orally, rectally, or by subcutaneous injection, intravenous infusion, inhalation or transdermal delivery.

### Claim 8 (depends on 7)

The method of claim 7, wherein S-oxybutynin is administered orally.

### Claim 9 (depends on 8)

The method of claim 8, wherein S-oxybutynin is administered in the form of a syrup.

### Claim 10 (depends on 8)

The method of claim 8, wherein S-oxybutynin is administered in the form of a tablet or a capsule.

### Claim 11 (depends on 10)

The method of claim 10, wherein S-oxybutynin is administered in sustained release form.

### Claim 12 (depends on 8)

The method of claim 8, wherein the amount administered orally is from about 1 mg to about 1 g per day.

### Claim 13 (depends on 8)

The method of claim 8, wherein the amount of S-oxybutynin, or a pharmaceutically acceptable salt thereof, administered is from about 25 mg to about 700 mg per day.

### Claim 14 (depends on 7)

The method of claim 7, wherein S-oxybutynin is administered by inhalation.

### Claim 15 (depends on 14)

The method of claim 14, wherein the amount administered by inhalation is from about 0.1 mg to about 100 mg per day.

### Claim 16 (depends on 7)

The method of claim 7, wherein S-oxybutynin is administered in the form of a transdermal patch.